Skip to main content

Advertisement

Table 1 Summary of major clinical trials on aerosol measles vaccines presented to the expert group for stage II of the CHNRI process

From: An evaluation of respiratory administration of measles vaccine for prevention of acute lower respiratory infections in children

Reference MV Strain Age group Seroconversion as defined by authors
A.Dilraj et al [46] MV-Schwarz ( s/c, aerosol),
MV- Edmonston-Zagreb ( s/c, aerosol)
992 participants
5-14 years
Seroconversion rates (defined as four fold increase in antibody level):
EZ Aerosol – 84.7%
EZ sc – 78.8%
SW Aerosol – 22.7%
SW sc – 62.6%
A.Dilraj et al [47] MV-Schwarz ( s/c),
MV- Edmonston-Zagreb ( s/c, aerosol)
337 participants
5-14 years
Seroconversion (defined as four fold increase in antibody level) at 6 years after revaccination:
EZ Aerosol – 86%
EZ sc – 73%
SW sc – 58%
J.A.Bellanti et al [48] MV- Edmonston-Zagreb ( s/c, aerosol) 49 participants
6-7 years
The mean Specific anti-measles IgG antibody:
EZ sc - 22.9 ± 4.6
EZ aerosol - 53.4 ± 9.4
Results are reported as mean _ µg/ml ± standard error of the mean
J.V.Bennett et al [49] MV-Schwarz ( s/c),
MV- Edmonston-Zagreb ( s/c, aerosol)
1624 participants
6-8 years
Change from seronegative to seropositive, >= 120 mIU/ml
EZ aerosol – 65%
EZ sc – 4%
SW sc – 23%
R.M.Wong-Chew et al [50] MV- Edmonston-Zagreb ( s/c, aerosol) 114 participants
11-13 months
Seroresponse rates as defined by four fold increase in antibody level:
EZ aerosol – 89.8%
EZ sc – 100%
R.M.Wong-Chew et al [51] MV- Edmonston-Zagreb ( s/c, aerosol) 129 participants
8-10 months
Seroresponse rates as defined by four fold increase in antibody level:
EZ Aerosol – 42%
EZ sc – 67%